Idera delaying HCV trial

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) will delay the start of a Phase II trial of HCV candidate IMO-2125 after histology data from a 26-week toxicology study showed atypical lymphocytic proliferation in rodents. Idera, which had planned to start the trial this quarter, now plans to wait until after it evaluates additional data from the rodent study and data from a similar study in non-human primates. Both sets of data are expected next half. ...